

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

Enveric Biosciences, Inc.

Form: 3

Date Filed: 2021-01-08

Corporate Issuer CIK: 890821

© Copyright 2021, Issuer Direct Corporation. All Right Reserved. Distribution of this document is strictly prohibited, subject to the terms of use.

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number: 3235-0104					
Estimated average burde	en hours				
per response	0.5				

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)								
Johnson David Ian (Month/Day/Year)			Issuer Name and Ticker or Trading Symbol Enveric Biosciences, Inc. [ENVB]					
(Last) (First) (Middle) C/O ENVERIC BIOSCIENCES, INC.,, 4851 TAMIAMI TRAIL N, SUITE 200	12/30/2020		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director			5. If Amendment, Date Original Filed(Month/Day/Year)		
(Street) NAPLES, FL 34103						6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)		Tabl	e I - Non-Deriva	ative Securities	Beneficially Ow	vned		
1.Title of Security (Instr. 4)	Amount of Securities Beneficially Owned (Instr. 4)			3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Nature of Indirect Beneficial Ownership (Instr. 5)			
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-0								
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.								
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
Title of Derivative Security (Instr. 4)	Date Exercisable and Expiration Date (Month/Day/Year) Date Expirati	d Expiration Date Underlying Derivation Underlying Derivation (Instr. 4)		Exercise Price of	of Derivative Security: Direct (D) or Indirect (I)	Nature of Indirect Beneficial Ownership (Instr. 5)		
	Exercisable Date	Title Amount or N	uniber of Shares		(Instr. 5)			

Reporting Owners

Reporting Owner Name / Address	Relationships					
neporting Owner Name / Address	Director	10% Owner	Officer	Other		
Johnson David Ian C/O ENVERIC BIOSCIENCES, INC., 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES, FL 34103	х		CEO and Chairman			

Signatures

/s/ David I. Johnson	01/08/2021
Signature of Reporting Person	Date

Explanation of Responses:

No securities are beneficially owned

- $^{\star}\,$ If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78f(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0104				
Estimated average burd	len hours				
per response	0.5				

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)												
Name and Address of Reporting Person Johnson David Ian		Date of Event Requiring Statem (Month/Day/Year)			at 3. Issuer Name and Ticker or Trading Symbol Enveric Biosciences, Inc. [ENVB]							
(Last) (First) C/O ENVERIC BIOSCIENCES, INC., TAMIAMI TRAIL N, SUITE 200	(Middle) , 4851	12/30/2	12/30/2020			Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director			5. If Amendment, Date Original Filed(Month/Day/Year)			
(Street) NAPLES, FL 34103							O and Chairman	6	ine) X_ Form file	ed by One Rep	t/Group Filing(Check Applicat porting Person an One Reporting Person	ble
(City) (State)	(Zip)			Т	able	I - Non-Deriv	ative Securities	Beneficia			in One reporting reason	
1. Title of Security (Instr. 4)				2. Amount of S Owned (Instr. 4)	ecuritie	es Beneficially	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature o (Instr. 5)	f Indirect	Beneficial	Ownership	
a currently valid	espond to	the collecti ntrol numb	ion of inforrer.	mation contair	ned in	this form are no	t required to respon			lisplays	SEC 1473 (7-02
Title of Derivative Security (Instr. 4)		Date Exercisable 3. Title and Amou		Amount of Securities 4. Conversion Derivative Security Exercise Prior		4. Conversion or Exercise Price of	5. Ownersl of Derivativ			of Indirect Beneficial ip		
		Date Exercisab	Expiratior le Date	Title Amount	or Nur	nber of Shares		or Indirect (Instr. 5)	(1)			
Reporting Owners												
Reporting Owner Name / Address	L .		elationship	s								
Johnson David Ian	Director 1	10% Owner	Officer		Other							
C/O ENVERIC BIOSCIENCES, INC., 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES, FL 34103	х		CEO an	d Chairman								

Signatures

/s/ David I. Johnson	01/08/2021
-Signature of Reporting Person	Date

Explanation of Responses:

No securities are beneficially owned

- $^{\star}\,$ If the form is filed by more than one reporting person,see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78f(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.